TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues-a comparative study of oligonucleotide length, design and chemistry

Nucleic Acids Research

Volumn 40, Issue 13, 2012, Pages 6135-6143

  Murray, Sue ^a   Ittig, Damian ^b   Koller, Erich ^a   Berdeja, Andres ^a   Chappell, Alfred ^a   Prakash, Thazha P ^a   Norrbom, Michaela ^a   Swayze, Eric E ^a   Leumann, Christian J ^b   Seth, Punit P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; DNA; LIPID; MESSENGER RNA; NITROGEN; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; SCAVENGER RECEPTOR BI; SODIUM CHLORIDE; TRIACYLGLYCEROL; TRICYCLODNA; UNCLASSIFIED DRUG; UREA;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAPHRAGM; DNA MODIFICATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROCNEMIUS MUSCLE; GENETIC TRANSFECTION; HEART; KIDNEY PARENCHYMA; LIVER PARENCHYMA; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUADRICEPS FEMORIS MUSCLE; SEQUENCE ANALYSIS;

ANIMALS; CELL LINE; LIVER; MALE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS B; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 84864062473     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks273     Document Type: Article

References (36)

1. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
2. Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S. et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 375, 998-1006.
3. Lares, M.R., Rossi, J.J. and Ouellet, D.L. (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol., 28, 570-579.
4. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M. and Stoffel, M. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature, 43, 685-689.
5. Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjarn, M., Hansen, H.F., Berger, U. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896-899.
6. Steffy, K., Allerson, C. and Bhat, B. (2011) Perspectives in MicroRNA therapeutics. Pharm. Technol., s18, s20-s22, s24.
7. Swayze, E.E. and Bhat, B. (2008) The Medicinal Chemistry of Oligonucleotides. In: Crooke, S.T. (ed.), Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. CRC Press, Boca Raton, pp. 143-182.
8. Prakash, T.P. and Bhat, B. (2007) 2'-Modified oligonucleotides for antisense therapeutics. Curr. Top. Med. Chem., 7, 641-649.
9. Veedu, R.N. and Wengel, J. (2010) Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem. Biodivers., 7, 536-542.
10. Herdewijn, P. (2010) Nucleic acids with a six-membered carbohydrate' mimic in the backbone. Chem. Biodiversity, 7, 1-59.
11. Leumann, C.J. (2002) DNA analogues: from supramolecular principles to biological properties. Bioorg. Med. Chem., 10, 841-854.
12. Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F., McGee, D., Guinosso, C.J., Kawasaki, A.M., Cook, P.D. and Freier, S.M. (1993) Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268, 14514-14522.
13. Seth, P.P., Siwkowski, A., Allerson, C.R., Vasquez, G., Lee, S., Prakash, T.P., Wancewicz, E.V., Witchell, D. and Swayze, E.E. (2009) Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem., 52, 10-13.
14. Seth, P.P., Allerson, C.R., Berdeja, A., Siwkowski, A., Pallan, P.S., Gaus, H., Prakash, T.P., Watt, A.T., Egli, M. and Swayze, E.E. (2010) An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom in LNA. J. Am. Chem. Soc., 132, 14942-14950.
15. Seth, P.P., Allerson, C.R., Siwkowski, A., Vasquez, G., Berdeja, A., Migawa, M.T., Gaus, H., Prakash, T.P., Bhat, B. and Swayze, E.E. (2010) Configuration of the 50-methyl group modulates the biophysical and biological properties of locked nucleic acid (LNA) oligonucleotides. J. Med. Chem., 53, 8309-8318.
16. Prakash, T.P., Siwkowski, A., Allerson, C.R., Migawa, M.T., Lee, S., Gaus, H.J., Black, C., Seth, P.P., Swayze, E.E. and Bhat, B. (2010) Antisense oligonucleotides containing conformationally constrained 2', 4'-(N-methoxy)aminomethylene and 2', 4'-aminooxymethylene and 2'-O, 4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. J. Med. Chem., 53, 1636-1650.
17. Egli, M., Pallan, P.S., Allerson, C.R., Prakash, T.P., Berdeja, A., Yu, J., Lee, S., Watt, A., Gaus, H., Bhat, B. et al. (2011) Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 30-fluoro hexitol nucleic acid (FHNA and ara-FHNA) modified oligonucleotides. J. Am. Chem. Soc., 133, 16642-16649.
18. Renneberg, D. and Leumann, C.J. (2002) Watson-Crick base-pairing properties of tricyclo-DNA. J. Am. Chem. Soc., 124, 5993-6002.
19. Ittig, D., Liu, S., Renneberg, D., Schumperli, D. and Leumann, C.J. (2004) Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA. Nucleic Acids Res., 32, 346-353.
20. Seth, P.P., Vasquez, G., Allerson, C.A., Berdeja, A., Gaus, H., Kinberger, G.A., Prakash, T.P., Migawa, M.T., Bhat, B. and Swayze, E.E. (2010) Synthesis and biophysical evaluation of 2', 4'-constrained 2'O-methoxyethyl and 2', 4'-constrained 2'O-ethyl nucleic acid analogues. J. Org. Chem., 75, 1569-1581.
21. Koller, E., Vincent, T.M., Chappell, A., De, S., Manoharan, M. and Bennett, C.F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res., 39, 4795-4807.
22. Dean, N.M., McKay, R., Condon, T.P. and Bennett, C.F. (1994) Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem., 269, 16416-16424.
23. Dean, N.M. and Griffey, R.H. (1997) Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 7, 229-233.
24. Altmann, K.H., Martin, P., Dean, N.M. and Monia, B.P. (1997) Second generation antisense oligonucleotides-inhibition of pkc-alpha and C-raf kinase expression by chimeric oligonucleotides incorporating 6'-substituted carbocyclic nucleosides and 2'-O-ethylene glycol substituted ribonucleosides. Nucleosides Nucleotides Nucleic Acids, 16, 917-926.
25. Teplova, M., Minasov, G., Tereshko, V., Inamati, G.B., Cook, P.D., Manoharan, M. and Egli, M. (1999) Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol., 6, 535-539.
26. Martin, P. (2003) Ein neuer Zugang zu 2'-O-(2-Methoxyethyl) ribonucleosiden ausgehend von D-Glucose Helv. Chim. Acta, 86, 204.
27. Geary, R.S., Yu, R.Z. and Levin, A.A. (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Invest. Drugs, 2, 562-573.
28. Straarup, E.M., Fisker, N., Hedtjarn, M., Lindholm, M.W., Rosenbohm, C., Aarup, V., Hansen, H.F., Orum, H., Hansen, J.B. and Koch, T. (2010) Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res., 38, 7100-7111.
29. Ittig, D., Gerber, A.-B. and Leumann, C.J. (2010) Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes. Nucleic Acids Res., 39, 373-380.
30. Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H. and Krieger, M. (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 271, 518-520.
31. Bartosch, B., Vitelli, A., Granier, C., Goujon, C., Dubuisson, J., Pascale, S., Scarselli, E., Cortese, R., Nicosia, A. and Cosset, F.-L. (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem., 278, 41624-41630.
32. Rodrigues, C.D., Hannus, M., Prudencio, M., Martin, C., Goncalves, L.A., Portugal, S., Epiphanio, S., Akinc, A., Hadwiger, P., Jahn-Hofmann, K. et al. (2008) Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe, 4, 271-282.
33. Freier, S.M., Alkema, D., Sinclair, A., Neilson, T. and Turner, D.H. (1985) Contributions of dangling end stacking and terminal base-pair formation to the stabilities of XGGCCP, XCCGGP, XGGCCYP, and XCCGGYP helixes. Biochemistry, 24, 4533-4539.
34. Freier, S.M. and Altmann, K.H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res., 25, 4429-4443.
35. Krieg, A.M. (1999) Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta, 1489, 107-116.
36. Geary, R.S., Wancewicz, E., Matson, J., Pearce, M., Siwkowski, A., Swayze, E. and Bennett, F. (2009) Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem. Pharmacol., 78, 284-291.